Gαi1/3 signaling mediates IL-5-induced eosinophil activation and type 2 inflammation in eosinophilic chronic rhinosinusitis.

Background: Uncontrolled severe eosinophilic chronic rhinosinusitis (eCRS) is associated with elevated levels of Th2 cells and raised immunoglobulin concentrations in nasal polyp tissue. eCRS is characterized by high eosinophilic infiltration and type 2 inflammation. Gαi1/3 proteins participate in allergic inflammation by regulating immune cells.

Bioengineered NanoAid synergistically targets inflammatory pro-tumor processes to advance glioblastoma chemotherapy.

Through transcriptomic analysis of patient-derived glioblastoma tissues, we identify an overactivation of inflammatory pathways that contribute to the development of a tumor-promoting microenvironment and therapeutic resistance. To address this critical mechanism, we present NanoAid, a biomimetic nanoplatform designed to target inflammatory pro-tumor processes to advance glioblastoma chemotherapy. NanoAid employs macrophage-membrane-liposome hybrids to optimize the delivery of COX-2 inhibitor parecoxib and paclitaxel.

The Ethical and Practical Issues of Guiding Uninsured Patients with Skin Cancer to Resources that Alleviate Financial Burden.

A skin cancer diagnosis imposes not only a psychosocial burden but also significant financial stress due to treatment costs. This stress can intensify dramatically for patients who suddenly lose health insurance coverage, especially considering that uninsured patients are more likely to experience late-stage melanoma diagnoses and face a higher overall incidence of skin cancer than the general population. Dermatology clinics and physicians serving uninsured and vulnerable populations should be equipped with resources and strategies to ensure these patients receive adequate and timely care.

New Kidney-After-Heart Allocation Policy in the United States: Who would benefit from a rescue kidney?

Purpose: The new rescue kidney policy in the United States was implemented in June 2023. To estimate its potential impact, we investigated a historic cohort of heart transplant (HT) recipients who would have been eligible for a kidney-after-heart transplant under this policy.

Methods: Adult heart-only recipients from 1/1/2000 to 3/31/2023 in the United Network for Organ Sharing database were categorized by retroactively applying eligibility criteria from the new policy: eGFR≤20mL/min, CrCl≤20mL/min, or dialysis 60-365 days post-HT.